Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Jun 25, 2023 1:41pm
470 Views
Post# 35513645

Nice jump in SP, but why? ……Blockbuster potential

Nice jump in SP, but why? ……Blockbuster potential

I have been following Onc since 2001. ...yes a long time.
Have been in & out of ownership multiple times within that window.
regardless of my shareholdings, always have been watching.

I do presently own the highest # of shares in my history.
 

Chat rooms in their finest realm are educational, I have tried to always post substantial background.
If/ when I'm offering an opinion, I preface it as such.

Taking a journey way back.....way way back.
ONC was foremen as a corporation with only one goal:
" To prove Pelareorep efficiency as a cancer treatment", " then to sell or partner to get the virus to market".
If you doubt that check on articles of incorporation found in SEDAR, around Y2K.

The first discovery was that Pela can be injected I.V. And the virus will find the cancer.
Proven 1000s of times, it only multiplies in cancer cellls!
They tried the single drug approach, to little avail. Many things were discovered.
Most of oncolytic biotech science has been proven over the last 3-4 years.
The co- therapy route has been chosen as best opportunity.
The published Pancreatic results just a few months ago, has quickly lead to FDA fast track & now HUGE recognition & invite from PanCAN.
Moving the Time Machine to today.
ONC has two phase 3 ready opportunities. Being pancreatic cancer & mbc
They also have cooking on the back burner the following;
Trial with Incyte 
M.M updates coming soon.
Exceptional results with CAR-T  lab trials. Awaiting further direction.
The Goblet trial ( includes panc) with Roche.
In- place partnership with A.N.

Most current & significant?
After 20+ years of trials, relationships & developments of technology it has been boiled down to " more details within 90 days"
That BTW is the most direct & detailed information Onc has EVER published.

now my opinion....
what can happen with the 90 days?
first that timeline coincides with pending updates on many trials.
My guess? Roche will either partner with or buy- out oncolytics biotech.
similar to what has been seen outside of onc land. There could be a $$ infusion, followed by a buy- out.
Should they go the partner route. Onc becomes a $15-$20;trading range.
We might well see above $10 within next few weeks regardless.
a buy- out?
That 100% depends on when.
Simple risk management, the earlier the lower the price.
A buyout once phase 3 started,  easy the $5-8 billion numbers mentioned.
Once phase 3 data stars to show efficacy, easy $10bill++
prior to phase 3?

depends on what Roche knows about the addional goblet numbers.
could be the $1bill- $3 bill range.
regardless

big picture, Onc has never in its history been at this juncture with so many possibilities.
BTW the long term historic SP is $160/ps CDN
rright now the trading SP is beyond silly low.

it might spike both up & down as the day traders have their way.
just remember within 90 days ( 85 now), there will be a follow up & phase 3 trial announcement.
who knows what else's can pop up.



 

<< Previous
Bullboard Posts
Next >>